Suchergebnisse - "Wilson, R H"

PubPharm (426)

1

High-speed quantitative optical imaging of absolute metabolism in the rat cortex

enthalten in: bioRxiv.org | 2021

von Wilson, R. | Crouzet, C. | Torabzadeh, M. | +5

2

Cerebral perfusion and metabolism coupling during a critical time window provides rapid assessment of cardiac arrest severity and prognosis in a preclinical model

enthalten in: bioRxiv.org | 2019

von Wilson, R. | Crouzet, C. | Torabzadeh, M. | +6

3

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours

enthalten in: European journal of cancer (Oxford, England : 1990) | 2018

von Arkenau, H. | Italiano, A. | Mak, G. | +15

4

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2018

von Basu, B. | Krebs, M. | Sundar, R. | +25

5

Plant RuBisCo assembly in E. coli with five chloroplast chaperones including BSD2

enthalten in: Science (New York, N.Y.) | 2017

von Aigner, H. | Wilson, R. | Bracher, A. | +4

CommentIn: Science. 2017 Dec 8;358(6368):1253-1254. - PMID 29217555

6

Cyclin A/CDK2 phosphorylation of CIZ1 blocks replisome formation and initiation of mammalian DNA replication

enthalten in: Journal of cell science | 2015

von Copeland, N. | Sercombe, H. | Wilson, R. | +1

7

EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer

enthalten in: Clinical cancer research | 2015

von Dunne, P. | Dasgupta, S. | Blayney, J. | +14

8

A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3) : a model for randomised controlled trials in the era of personalised medicine?

enthalten in: British journal of cancer | 2014

von Maughan, T. | Meade, A. | Adams, R. | +22

9

A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?

enthalten in: The British journal of cancer | 2014

von Maughan, T. | Meade, A. | Adams, R. | +22

10

A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma

enthalten in: Investigational new drugs | 2014

von Turkington, R. | Purcell, C. | James, C. | +7

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[43]